Parenteral Anticoagulation with the Heparinoid Lomoparan (Org 10172) in Patients with Heparin Induced Thrombocytopenia and Thrombosis

Summary

Progressive thrombocytopenia may develop in as many as 5% of patients receiving heparin anticoagulation. In these patients, the risk of thromboembolic complications as well as continued thrombocytopenia necessitates discontinuation of heparin and initiation of an alternative anticoagulant when indicated. The heparinoid Lomoparan (Org 10172) is a mixture of several nonheparin low molecular weight glycosaminoglycans with proven anticoagulant efficacy that is generally non-reactive with platelets in the presence of plasma from patients with heparin induced thrombocytopenia, whereas standard heparin will induce platelet aggregation. We evaluated the role of heparinoid as a potential alternative anticoagulant in patients with heparin induced thrombocytopenia. During a 6 month period, we identified six patients with heparin induced thrombocytopenia who required an alternative parenteral anticoagulant, four as primary treatment for specific medical problem, and two as anticoagulation during a necessary surgical procedure. Heparinoid was used successfully in both medical and surgical patients requiring parenteral anticoagulation. In no case was there an exacerbation of the thrombocytopenia nor thromboembolic complications while on heparinoid therapy. Three of our patients sustained hemorrhagic complications, predominantly in the post-surgical setting in association with elevated anti-factor Xa levels and additional anticoagulant agents. We feel that these results confirm the utility of heparinoid anticoagulation in a select subset of patients with heparin induced thrombocytopenia who require continued parenteral anticoagulation.

• References

• 1 King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535-540
• 2 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annu Rev Med 1989; 40: 31-44
• 3 Roussi JH, Houbouyan LL, Goguel AF. Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet 1984; 1: 1183
• 4 Vitoux J-F, Mathieu J-F, Roncato M, Fiessinger J-N, Aiach M. Heparin-associated thrombocytopenia treatment with low molecular weight heparin. Thromb Haemostas 1986; 55: 37-39
• 5 Harenberg J, Zimmerman R, Schwarz F, Kubler W. Treatment of heparin-induced thrombocytopenia with thrombosis by new heparinoid. Lancet 1983; 1: 986-987
• 6 Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73: 1592-1596
• 7 Oosta GM, Gardner WT, Beeler DL, Rosenberg RD. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci 1981; 78: 829-833
• 8 Salzman EW, Rosenberg RD, Smith MG, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
• 9 Blockmans D, Bounameaux H, Vermylen J, Verstraete M. Heparin-induced thrombocytopenia. Platelet aggregation studies in the presence of heparin fractions or semi-synthetic analogues of various molecular weights and anticoagulant activities. Thromb Haemostas 1986; 55: 90-93
• 10 Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution. J Vase Surg 1986; 4: 522-528
• 11 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 37: 237-246
• 12 Greenberg CS, Devine DV, McCrae KM. Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads. Am J Clin Pathol 1987; 87: 94-100
• 13 Teien AN, Lie M, Abelgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor Xa. Thromb Res 1976; 8: 413
• 14 Doherty DC, Ortei TL, de Bruijn N, Greenberg CS, van Tright III P. “Heparin-free” cardiopulmonary bypass: First reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990; 73: 562-565
• 15 Sobel M, Adelman B, Szentpetery S, Hoffman M, Posner MP, Jenvey W. Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism. J Vase Surg 1988; 8: 395-401
• 16 Samama MM, Desnoyers PC, Kwaan HC. Miscellaneous: dextran, dermatan sulfate, low molecular weight heparinoids (Org 10172), pentosan polysulfate (SP -4), defibrinating agents (ancrod and reptilase). In: Clinical Thrombosis. Kwaan HC, Samama MM. (eds). CRC Press, Inc.; Boca Raton, CA: 1989. pp 527-534
• 17 Makhoul RG, McCann RL, Austin EH, Greenberg CS, Lowe JE. Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. Ann Thorac Surg 1987; 43: 617-621
• 18 Laster J, Elfrink R, Silver D. Reexposure to heparin of patients with heparin-associated antibodies. J Vase Surg 1989; 9: 677-682
• 19 Kappa JR, Cottrell ED, Berkowitz HD, Fisher CA, Sobel M, Ellison N, Addonizio Jr VP. Carotid endarterectomy in patients with heparin-induced platelet activation: comparative efficacy of aspirin and iloprost (ZK 36374). J Vase Surg 1987; 5: 693-701
• 20 Kappa JR, Horn III MK, Fisher CA, Cottrell ED, Ellison N, Addonizio Jr VP. Efficacy of iloprost (ZK 36374) versus aspirin in preventing heparin-induced platelet activation during cardiac operations. J Thorac Cardiovasc Surg 1987; 94: 405-413
• 21 Topol EJ, Ellis SG, Califf RM. et al Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J Am Coll Cardiol 1989; 14: 877-884
• 22 Horellou MH, Conard J, Lecrubier C. et al Persistent heparin induced thrombocytopenia despite therapy with low molecular weight heparin. Thromb Haemostas 1984; 51: 134
• 23 Cohen JI, Cooper MR, Greenberg CS. Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch Intern Med 1985; 145: 1725-1726
• 24 Vender JS, Matthew EB, Silverman IM, Konowitz H, Dau P. Heparin-associated thrombocytopenia: Alternative managements. Anesth Analg 1986; 65: 520-522
• 25 Bradbrook ID, Magnani HN, Moelker HCT, Morrison PJ, Robinson J, Rogers HJ, Spector RG, van Dinther T, Wijnand H. ORG 10172: A low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 1987; 23: 667-675